Liang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Liang Liu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Chuan Dong
16 shared publications- Donald Pizzo
Department of Pathology, School of Medicine, University of California San Diego, La Jolla, CA, USA
16 shared publications - Lin Yang
Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
16 shared publications - Minghui Cao
Department of Pathology, University of California–San Diego, La Jolla, CA 92093, USA
16 shared publications - Shizhen Emily Wang
Department of Pathology, University of California San Diego, La Jolla, USA
16 shared publications - Xianhui Ruan
Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
16 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S2. The overexpression and silencing of LIMS2 in lung adenocarcinoma cells.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S2. The overexpression and silencing of LIMS2 in lung adenocarcinoma cells.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Table S1. The relationship analysis between LIMS2 immunohistochemistry score and clinicopathological characteristics of lung adenocarcinoma patients.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Table S1. The relationship analysis between LIMS2 immunohistochemistry score and clinicopathological characteristics of lung adenocarcinoma patients.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S1. LIMS2 was decreased in lung adenocarcinoma cell lines.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S1. LIMS2 was decreased in lung adenocarcinoma cell lines.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Data from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Lung cancer is a highly malignant tumor and prone to recurrence and metastasis. Adenocarcinoma is the most common subtype. LIM zinc finger domain containing 2 (LIMS2) was reported to inhibit growth and metastasis of several tumors, whereas its role in lung adenocarcinoma remains unclear. This study aims to expound the function of LIMS2 in lung adenocarcinoma. The analysis from medical databanks showed that LIMS2 was lowly expressed in lung adenocarcinoma specimens, compared with the normal lung tissues, and our clinical data demonstrated that LIMS2 expression was associated with the tumor–node–metastasis stage of patients with lung adenocarcinoma. Gain- and loss-of-function experiments revealed that LIMS2 suppressed proliferation, invasion, migration, epithelial–mesenchymal transition of lung adenocarcinoma cells, delayed xenograft and orthotopic growth, and blocked distant metastasis and lymph infiltration in nude mice. The medium supernatant from LIMS2-overexpressed lung adenocarcinoma cells intercepted the activation of fibroblasts from lung cancer. The coimmunoprecipitation results demonstrated that an E3 ubiquitin ligase ring finger and CHY zinc finger domain containing 1 (RCHY1) interacted with LIMS2 and mediated its K48 ubiquitination and degradation. LIMS2 overexpression reversed the promoting effects of RCHY1 on proliferation, migration, and lung cancer–fibroblast activation of lung adenocarcinoma cells. In conclusion, decreased LIMS2 may mediate the tumor-promoting role of RCHY1 in lung adenocarcinoma cells.Implications:These findings may provide novel diagnostic markers and therapeutic targets for lung adenocarcinoma in clinic.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Lung cancer is a highly malignant tumor and prone to recurrence and metastasis. Adenocarcinoma is the most common subtype. LIM zinc finger domain containing 2 (LIMS2) was reported to inhibit growth and metastasis of several tumors, whereas its role in lung adenocarcinoma remains unclear. This study aims to expound the function of LIMS2 in lung adenocarcinoma. The analysis from medical databanks showed that LIMS2 was lowly expressed in lung adenocarcinoma specimens, compared with the normal lung tissues, and our clinical data demonstrated that LIMS2 expression was associated with the tumor–node–metastasis stage of patients with lung adenocarcinoma. Gain- and loss-of-function experiments revealed that LIMS2 suppressed proliferation, invasion, migration, epithelial–mesenchymal transition of lung adenocarcinoma cells, delayed xenograft and orthotopic growth, and blocked distant metastasis and lymph infiltration in nude mice. The medium supernatant from LIMS2-overexpressed lung adenocarcinoma cells intercepted the activation of fibroblasts from lung cancer. The coimmunoprecipitation results demonstrated that an E3 ubiquitin ligase ring finger and CHY zinc finger domain containing 1 (RCHY1) interacted with LIMS2 and mediated its K48 ubiquitination and degradation. LIMS2 overexpression reversed the promoting effects of RCHY1 on proliferation, migration, and lung cancer–fibroblast activation of lung adenocarcinoma cells. In conclusion, decreased LIMS2 may mediate the tumor-promoting role of RCHY1 in lung adenocarcinoma cells.Implications:These findings may provide novel diagnostic markers and therapeutic targets for lung adenocarcinoma in clinic.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S4. LIMS2 reversed the effects of RCHY1 on lung adenocarcinoma cells.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S4. LIMS2 reversed the effects of RCHY1 on lung adenocarcinoma cells.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S5. The transcriptome analysis of A549 cells with LIMS2 overexpression.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S5. The transcriptome analysis of A549 cells with LIMS2 overexpression.
- Open Access
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S3. Downregulation of LIMS2 in lung adenocarcinoma cells promoted activation of lung cancer-fibroblasts.
- 3 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Figure S3. Downregulation of LIMS2 in lung adenocarcinoma cells promoted activation of lung cancer-fibroblasts.
- 6 February 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 24 (6) , 473-486
LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Lung cancer is a highly malignant tumor and prone to recurrence and metastasis. Adenocarcinoma is the most common subtype. LIM zinc finger domain containing 2 (LIMS2) was reported to inhibit growth and metastasis of several tumors, whereas its role in lung adenocarcinoma remains unclear. This study aims to expound the function of LIMS2 in lung adenocarcinoma. The analysis from medical databanks showed that LIMS2 was lowly expressed in lung adenocarcinoma specimens, compared with the normal lung tissues, and our clinical data demonstrated that LIMS2 expression was associated with the tumor–node–metastasis stage of patients with lung adenocarcinoma. Gain- and loss-of-function experiments revealed that LIMS2 suppressed proliferation, invasion, migration, epithelial–mesenchymal transition of lung adenocarcinoma cells, delayed xenograft and orthotopic growth, and blocked distant metastasis and lymph infiltration in nude mice. The medium supernatant from LIMS2-overexpressed lung adenocarcinoma cells intercepted the activation of fibroblasts from lung cancer. The coimmunoprecipitation results demonstrated that an E3 ubiquitin ligase ring finger and CHY zinc finger domain containing 1 (RCHY1) interacted with LIMS2 and mediated its K48 ubiquitination and degradation. LIMS2 overexpression reversed the promoting effects of RCHY1 on proliferation, migration, and lung cancer–fibroblast activation of lung adenocarcinoma cells. In conclusion, decreased LIMS2 may mediate the tumor-promoting role of RCHY1 in lung adenocarcinoma cells. Implications: These findings may provide novel diagnostic markers and therapeutic targets for lung adenocarcinoma in clinic.
- 6 February 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 24 (6) , 473-486
LIMS2 Regulates Lung Adenocarcinoma Progression and Suppresses the Activation of Cancer-Associated Fibroblast
Lung cancer is a highly malignant tumor and prone to recurrence and metastasis. Adenocarcinoma is the most common subtype. LIM zinc finger domain containing 2 (LIMS2) was reported to inhibit growth and metastasis of several tumors, whereas its role in lung adenocarcinoma remains unclear. This study aims to expound the function of LIMS2 in lung adenocarcinoma. The analysis from medical databanks showed that LIMS2 was lowly expressed in lung adenocarcinoma specimens, compared with the normal lung tissues, and our clinical data demonstrated that LIMS2 expression was associated with the tumor–node–metastasis stage of patients with lung adenocarcinoma. Gain- and loss-of-function experiments revealed that LIMS2 suppressed proliferation, invasion, migration, epithelial–mesenchymal transition of lung adenocarcinoma cells, delayed xenograft and orthotopic growth, and blocked distant metastasis and lymph infiltration in nude mice. The medium supernatant from LIMS2-overexpressed lung adenocarcinoma cells intercepted the activation of fibroblasts from lung cancer. The coimmunoprecipitation results demonstrated that an E3 ubiquitin ligase ring finger and CHY zinc finger domain containing 1 (RCHY1) interacted with LIMS2 and mediated its K48 ubiquitination and degradation. LIMS2 overexpression reversed the promoting effects of RCHY1 on proliferation, migration, and lung cancer–fibroblast activation of lung adenocarcinoma cells. In conclusion, decreased LIMS2 may mediate the tumor-promoting role of RCHY1 in lung adenocarcinoma cells. Implications: These findings may provide novel diagnostic markers and therapeutic targets for lung adenocarcinoma in clinic.
- Open Access
- 10 January 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (2) , e40332
Comparative genomic analysis unveiling the mutational landscape associated with premalignant lesions and early-stage gastric cardia cancer
This study enrolled 10 patients diagnosed with premalignant lesions and early-stage gastric cardia adenocarcinoma (GCA), confirmed through endoscopic examination. These patients were subjected to next-generation sequencing (NGS) using a customized 1123-gene panel to identify genetic alterations and signaling pathways. The results were compared to stage IIB to IV GCA samples from the cancer genome atlas (TCGA) and a cohort of Hong Kong patients. The study provides insights into the molecular drivers of GCA progression, with potential therapeutic implications. A total of 10 patients diagnosed with premalignant and early-stage GCA were subjected to NGS targeted 1123-panal testing. Genetic alterations characteristics and signaling pathways were defined and analyzed. These findings were compared with the mutation features of stage IIB to IV GCA samples from the TCGA and another GCA cohort of HongKong patients (HK cohort). Additionally, therapeutic implications were also evaluated. In premalignant lesions and early-stage GCA, driver genes, such as TP53, ARIDA and LRP1B were found to have high mutation rates and showed no significantly different in driver gene mutation and tumor mutational burden with stage IIB to IV GCA in both the HK and TCGA-GCA cohorts. However, EPHA2 showed a significantly higher mutation rate in premalignant and early-stage GCA compared to IIB to IV GCA. The majority of 10 cancer-related signaling pathways were found to be activated in premalignant and early-stage GCA. Furthermore, 80% patients had corresponding potential therapeutic inhibitors based on molecular mutation results in our cohort. Certain mutational characteristics involved in the occurrence and progression of GCA are already present in premalignant lesions and early-stage GCA, which can be assessed and prevented through early molecular testing. Additionally, EPHA2 mutations are more common in premalignant lesions and early-stage GCA, which provided potential biomarkers for the diagnosis and detection of premalignant lesions and early-stage GCA.
- 10 January 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (2) , e40332
Open AccessComparative genomic analysis unveiling the mutational landscape associated with premalignant lesions and early-stage gastric cardia cancer
This study enrolled 10 patients diagnosed with premalignant lesions and early-stage gastric cardia adenocarcinoma (GCA), confirmed through endoscopic examination. These patients were subjected to next-generation sequencing (NGS) using a customized 1123-gene panel to identify genetic alterations and signaling pathways. The results were compared to stage IIB to IV GCA samples from the cancer genome atlas (TCGA) and a cohort of Hong Kong patients. The study provides insights into the molecular drivers of GCA progression, with potential therapeutic implications. A total of 10 patients diagnosed with premalignant and early-stage GCA were subjected to NGS targeted 1123-panal testing. Genetic alterations characteristics and signaling pathways were defined and analyzed. These findings were compared with the mutation features of stage IIB to IV GCA samples from the TCGA and another GCA cohort of HongKong patients (HK cohort). Additionally, therapeutic implications were also evaluated. In premalignant lesions and early-stage GCA, driver genes, such as TP53, ARIDA and LRP1B were found to have high mutation rates and showed no significantly different in driver gene mutation and tumor mutational burden with stage IIB to IV GCA in both the HK and TCGA-GCA cohorts. However, EPHA2 showed a significantly higher mutation rate in premalignant and early-stage GCA compared to IIB to IV GCA. The majority of 10 cancer-related signaling pathways were found to be activated in premalignant and early-stage GCA. Furthermore, 80% patients had corresponding potential therapeutic inhibitors based on molecular mutation results in our cohort. Certain mutational characteristics involved in the occurrence and progression of GCA are already present in premalignant lesions and early-stage GCA, which can be assessed and prevented through early molecular testing. Additionally, EPHA2 mutations are more common in premalignant lesions and early-stage GCA, which provided potential biomarkers for the diagnosis and detection of premalignant lesions and early-stage GCA.
- Open Access
- 5 June 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (6) , 211-216
Growth inhibition of subcutaneous tumor with glioma cells in nude mice by silencing TLR4
This study investigated the regulatory impact of Toll-like receptor 4 (TLR4) gene on glioma cell proliferation and apoptosis, elucidating the molecular mechanisms underlying TLR4-induced growth inhibition in vivo. U-87MG-Sh and U-87MG-NC cells, with silenced TLR4 and negative control plasmid respectively, were established. Eighteen nude mice, divided into transfection, negative control, and blank control groups, were inoculated with corresponding cells. Over four weeks, the transfection group exhibited significantly reduced tumor growth rates, smaller mass and volume, and lower growth activity compared to controls. Histological analysis revealed sparse tumor cells, increased fibrous connective tissue, and slower angiogenesis in the transfection group. Flow cytometry demonstrated a lower proliferation index and increased G0/1 cell count in the transfection group. mRNA levels of TLR4, NF-κB, and CyclinD1 were significantly lower in the transfection group. TLR4 silencing correlated with U-87MG cell proliferation regulation, growth inhibition, NF-κB and CyclinD1 modulation, and induction of cell cycle arrest and apoptosis. These findings suggest TLR4 as a potential gene therapy target for glioma.
- 5 June 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (6) , 211-216
Open AccessGrowth inhibition of subcutaneous tumor with glioma cells in nude mice by silencing TLR4
This study investigated the regulatory impact of Toll-like receptor 4 (TLR4) gene on glioma cell proliferation and apoptosis, elucidating the molecular mechanisms underlying TLR4-induced growth inhibition in vivo. U-87MG-Sh and U-87MG-NC cells, with silenced TLR4 and negative control plasmid respectively, were established. Eighteen nude mice, divided into transfection, negative control, and blank control groups, were inoculated with corresponding cells. Over four weeks, the transfection group exhibited significantly reduced tumor growth rates, smaller mass and volume, and lower growth activity compared to controls. Histological analysis revealed sparse tumor cells, increased fibrous connective tissue, and slower angiogenesis in the transfection group. Flow cytometry demonstrated a lower proliferation index and increased G0/1 cell count in the transfection group. mRNA levels of TLR4, NF-κB, and CyclinD1 were significantly lower in the transfection group. TLR4 silencing correlated with U-87MG cell proliferation regulation, growth inhibition, NF-κB and CyclinD1 modulation, and induction of cell cycle arrest and apoptosis. These findings suggest TLR4 as a potential gene therapy target for glioma.